Shree Pacetronix Q1 PAT up 13.4% YoY to ₹0.76 Cr; Revenue dips 8.2%
Shree Pacetronix reported a mixed Q1 FY27 with standalone revenue declining 8.2% YoY to ₹4.90 Cr. Despite the top-line dip, Profit After Tax (PAT) grew 13.4% YoY to ₹0.76 Cr, primarily driven by a 78.7% reduction in finance costs. Sequentially, performance was weaker with revenue and PAT falling 8.7% and 21.6% respectively compared to Mar 2026. A significant highlight is the increase in promoter holding to 36.44% from 31.7% in the previous quarter.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its Q1 FY27 results showing a contraction in revenue but improved bottom-line efficiency due to lower interest expenses and cost control.
ஏன் இது முக்கியம்For a micro-cap company with a ₹50 Cr market cap, maintaining double-digit PAT growth and increasing promoter skin-in-the-game are positive signals, though the revenue decline warrants caution regarding market share.
Revenue (Q1 FY27): ₹4.90 கோடிPAT (Q1 FY27): ₹0.76 கோடிYoY Revenue Growth: -8.2%YoY PAT Growth: +13.4%Promoter Holding (Total): 36.44%Finance Costs (Q1): ₹2.42 லட்சம்
📅 குறுகிய காலம்The stock may remain range-bound as the market balances the revenue contraction against the improved profitability and promoter buying.
📈 நீண்ட காலம்The company's high ROCE (23.3%) and low debt-to-equity (0.15) provide a stable foundation, but long-term value creation depends on scaling its medical equipment revenue beyond the current ₹22 Cr TTM level.
⚠ அபாய எச்சரிக்கைகள்
- Revenue contraction on both YoY and QoQ basis
- Small scale of operations (Micro-cap risk)
- Promoter pledge remains at 3.44% of total capital
👀 கவனிக்க வேண்டியவை
Investors should monitor the 'Life Saving Devices' segment for signs of revenue recovery and track the impact of the increased promoter stake on corporate governance and growth strategy.
